What You Should Know:
– 4C Medical Technologies, a privately-held medical technology company focused on the development of minimally invasive therapies for structural heart disease raises $35.4M in Series C funding was led by MicroPort CardioFlow Medtech Corporation (HKEX:2160).
– The Company’s AltaValve® would be the first MR treatment with atrial-only fixation that is designed to minimize known issues associated with current TMVR technologies, which rely on placement and fixation within the native mitral annulus.
– As part of the closing, 4C Medical also announced the appointment of Saravana Kumar, PhD as its President & Chief Executive Officer. Dr. Kumar has served as the Company’s interim President and CEO since March 2021 after having previously served as the Company’s Vice President of R&D and Operations since November 2017.
